 "Sun Pharma extends savings card program for cancer drug in US")
Sun Pharma has announced that its Spanish partner Almirall SL has applied for a regulatory approval for psoriasis drug tildrakizumab with the European Medicines Agency (EMA). Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis.
In July 2016, Almirall entered into a licensing agreement with Sun Pharma for the development and commercialisation of tildrakizumab for psoriasis in Europe. Under the terms of the signed agreement, Sun Pharma will continue to lead other indications, for which Almirall will have the right to primary negotiation. In addition, Almirall will be able to lead European studies, and participate
